Samsung Bioepis Announces New Data on Three Anti-TNF-α Biosimilar Molecules at the Annual European…
Business Wire IndiaSamsung Bioepis Co., Ltd. announced new clinical data on its anti-TNF-α portfolio of Benepali® (etanercept), Flixabi® (infliximab) and SB5 (adalimumab) investigational biosimilar candidate. The data will be…
Read More...
Read More...